Gabor Varju, MD
Pulmonary Disease · Great Falls, MTNPI 1235342999
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,596 of the $10,058 with a category attached, or 85.5%. 29 manufacturers reported payments, led by AstraZeneca at 24.9% of the total. Among pulmonary disease clinicians in MT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 434 payments — averaging $23.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- GSK$2K
- Boehringer Ingelheim$1K
- Intuitive Surgical$1K
- Actelion Pharmaceuticals US, Inc.$624
- Genentech USA, Inc.$510
- plus $2K from 23 others
What the payments were for
- Travel & lodging$1,11811%
- Food & beverage$8,59685%
- Education$3443%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 82 | $2,507 |
| GSK | 105 | $1,677 |
| Boehringer Ingelheim | 77 | $1,335 |
| Intuitive Surgical | 2 | $1,118 |
| Actelion Pharmaceuticals US, Inc. | 23 | $624 |
| Genentech USA, Inc. | 18 | $510 |
| Philips North America LLC | 27 | $418 |
| Grifols USA, LLC | 20 | $325 |
| Sanofi | 14 | $303 |
| Mylan Specialty L.p. | 12 | $227 |
| Regeneron Healthcare Solutions, Inc. | 8 | $148 |
| Viatris Specialty LLC | 6 | $126 |
| Merck | 5 | $98 |
| Sanofi-aventis U.S. LLC | 1 | $97 |
| Insmed, Inc. | 5 | $86 |
| Verona Pharma, Inc. | 3 | $65 |
| Sunovion Pharmaceuticals Inc. | 8 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $51 |
| Pulmonx Corporation | 1 | $42 |
| Novartis | 2 | $41 |
| United Therapeutics Corporation | 2 | $36 |
| Harmony Biosciences LLC | 2 | $32 |
| Advanced Respiratory, Inc | 2 | $32 |
| Jazz Pharmaceuticals Inc. | 2 | $28 |
| Circassia Inc. | 1 | $20 |
| Vivus LLC | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Pfizer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$1,099
- FASENRA$671
- SYMBICORT$468
- BREZTRI$328
- BREZTRI AEROSPHERE$254
- AIRSUPRA$125
- XOLAIR$104
How this compares
$10,058 in reported general payments places this provider in the 90th percentile of 43 pulmonary disease providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 159 | $140,334 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 81 | $65,611 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 76 | $63,178 |
| Spiriva RespimatTiotropium Bromide | 47 | $30,433 |
| Spiriva HandihalerTiotropium Bromide | 31 | $15,265 |
| SymbicortBudesonide/Formoterol Fumarate | 47 | $13,573 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 22 | $9,461 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 12 | $8,218 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 143 | $6,800 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 13 | $6,655 |
| Advair HfaFluticasone Propion/Salmeterol | 22 | $5,923 |
| Incruse ElliptaUmeclidinium Bromide | 15 | $4,970 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 27 | $4,962 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 12 | $2,987 |
| Ventolin HfaAlbuterol Sulfate | 39 | $2,444 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta | $1,677 | $154,765196 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat | $1,335 | $100,265136 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $2,507 | $87,402140 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 43 pulmonary disease providers in Montana.
Other pulmonary disease in Great Falls
- Megan SiskGreat Falls$20K
- John MazurGreat Falls$18K
- Merhala BalasubramaniamGreat Falls$1K
- Robert GrasseschiGreat Falls$458
- Sheela AhmedGreat Falls$158
- Sean DowGreat Falls$20
- Richard KearleyGreat Falls$16
- William KrauseGreat Falls$0
- Gregory LemenseBozeman$39K
- Bethany WeilerKalispell$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.